Learning Objectives & Overview
In this touchTALKS, Dr Enrico Heffler describes the rationale for targeting eosinophilic inflammatory pathways in respiratory inflammatory diseases and discusses the most recent advances in existing and emerging biological therapeutic agents.
After watching this activity, participants should be better able to:
- Understand the dynamics of eosinophils across the human body in wellness and disease
- Discuss clinical scenarios in which eosinophilic therapy may be beneficial
- Recognize how new eosinophilic therapies offer promise for the future treatment of eosinophil-mediated diseases
Faculty & Disclosures
Dr Enrico Heffler
Humanitas University of Milan, Italy
Enrico Heffler is an Assistant Professor in Respiratory Diseases at Humanitas University of Milan, Italy. He specializes in allergy, clinical immunology, personalized medicine, asthma and allergy. read more
He received his MD in 2003 from the University of Torino, Italy; he specialized in Allergy and Clinical Immunology in 2008 and received a PhD in Experimental Medicine and Therapy (Experimental and Clinical Pharmacology) in 2014 from the University of Torino. Between 2015 and 2017, he was Assistant Professor in Respiratory Diseases at the University of Catania. His main research interests are airway and systemic inflammation, disease control and pathogenic mechanisms of asthma (mainly severe asthma), chronic rhinosinusitis with nasal polyps and anaphylaxis. His research interests also include the pathogenesis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome), food allergies and epidemiological aspects of respiratory allergic diseases.
Dr Heffler discloses: advisory board and speaker fees from AstraZeneca, Circassia, GlaxoSmithKline, Nestlè Purina, Novartis, Sanofi-Genzyme, and Stallergenes-Greer.